Risperidone & Zotepine in the Treatment of Delirium

Status Terminated

Clinical Trial Summary

Delirium is an organic psychiatric syndrome characterized by fluctuating consciousness and impairment in perception, cognition and behavior. In hospitalized elderly, the prevalence of delirium ranges from 10% to 40%. If untreated, delirium is associated with significant morbidity and mortality. Treatment of delirium consists of identifying and managing underlying medical abnormalities and the associated psychiatric symptoms. Conventional antipsychotics have been the mainstay of treatment of agitation and psychosis associated with delirium; but their use is limited in terms of EPS side effects. Second-generation antipsychotic agents have been reported to have a lower incidence of extrapyramidal side effects and tardive dyskinesia which has resulted in their increased use in the treatment of delirious patients. However, there is still no consensus regarding standard pharmacologic treatment of this syndrome that takes use of second-generation antipsychotic agents into account.

Risperidone and zotepine have a lower incidence of EPS and are effective in treating disturbing psychotic behaviors. We hope to compare the efficacy and safety of risperidone and zotepine in the treatment of delirium and the correlation between the severity of delirium with autonomic dysfunction.

Clinical Trial Description

Qualified inpatients will be enrolled and randomly given a flexible-dose regimen of Risperidone or Zotepine. Autonomic dysfunction is checked using analysis of heart rate variability before any active drug given. The initial starting dose of each drug is 1mg(risperidone) or 50 mg(zotepine) once a day. The dosage was increased depending on the status of delirium during the first 7 days and will be adjusted until patients are maximally stabilized or until intolerable adverse events necessitated cessation. Risperidone or zotepine will be tapered off in 10 days when patients are considered stable. No concomitant psychotropic medications will be used during the study except for lorazepam, which are given for severe agitation or insomnia . Patients are assessed by another rater blinded to active drug at the time of enrollment, the subsequent 12, 24,and then assessed daily until discharge. The study period is estimated to be around 12 months upon the designed number of subjects are reached. ;

Study Design

Related Conditions & MeSH terms

Delirium

Clinical Trial Details

NCT number	NCT00622011
Study type	Interventional
Source	Changhua Christian Hospital
Contact
Status	Terminated
Phase	Phase 4
Start date	January 2008
Completion date	March 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04551508` - Delirium Screening 3 Methods Study
Recruiting	`NCT05891873` - Delirium in the (Neuro)Intensive/Critical Care in the Adult and Paediatric Czech Populations
Recruiting	`NCT06027788` - CTSN Embolic Protection Trial	N/A
Recruiting	`NCT04792983` - Cognition and the Immunology of Postoperative Outcomes
Recruiting	`NCT06194474` - Study on Biomarkers of Postoperative Delirium in Elderly Cardiac Surgery Patients
Completed	`NCT03095417` - Improving the Recovery and Outcome Every Day After the ICU	N/A
Completed	`NCT05395559` - Prevalence and Recognition of Cognitive Impairment in Hospitalized Patients: a Flash Mob Study
Terminated	`NCT03337282` - Incidence and Characteristics of Postoperative Cognitive Dysfunction in Elderly Quebec Francophone Patients
Not yet recruiting	`NCT04846023` - Pediatric Delirium Screening in the PICU Via EEG	N/A
Not yet recruiting	`NCT04538469` - Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
Not yet recruiting	`NCT03807388` - ReMindCare App for Patients From First Episode of Psychosis Unit.	N/A
Withdrawn	`NCT02673450` - PER3 Clock Gene Polymorphism, Clock Gene Expression and Delirium in the Intensive Care Unit.
Recruiting	`NCT03256500` - Transcranial Direct Current Stimulation for the Treatment of Delirium	N/A
Not yet recruiting	`NCT02892968` - ED Ultrasonographic Regional Anesthesia to Prevent Incident Delirium in Hip Fracture Patients	N/A
Completed	`NCT02890927` - Geriatric-CO-mAnagement for Cardiology Patients in the Hospital	N/A
Recruiting	`NCT03165539` - Cerebral Oxygen Desaturation and Post-Operative Delirium in Thoracic Surgical Patients
Completed	`NCT02518646` - DElirium prediCtIon in the intenSIve Care Unit: Head to Head comparisON of Two Delirium Prediction Models	N/A
Completed	`NCT02554253` - The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction	Phase 2
Recruiting	`NCT02305589` - The Clinical Changes Before and After Sugammadex in the Patients Undergoing Hip Surgery on the Aspect of Delirium	N/A
Completed	`NCT02628925` - Nu-DESC DK: The Danish Version of the Nursing Delirium Screening Scale	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Risperidone and Zotepine in the Treatment of Delirium

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms